Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions

Full text
Author(s):
Ferreira, Marcelo U. [1, 2] ; de Sousa, Tais Nobrega [3] ; Rangel, Gabriel W. [4] ; Johansen, Igor C. [1] ; Corder, Rodrigo M. [1] ; Ladeia-Andrade, Simone [5] ; Gil, Jose Pedro [6]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, SP - Brazil
[2] Nova Univ Lisbon, Inst Hyg & Trop Med, Global Hlth & Trop Med, Lisbon - Portugal
[3] Fiocruz MS, Rene Rachou Inst, Mol Biol & Malaria Immunol Res Grp, Belo Horizonte, MG - Brazil
[4] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 - USA
[5] Fiocruz MS, Inst Oswaldo Cruz, Parasit Dis Lab, Rio De Janeiro - Brazil
[6] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna - Sweden
Total Affiliations: 6
Document type: Journal article
Source: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 15, p. 9-24, APR 2021.
Web of Science Citations: 2
Abstract

Emerging antimalarial drug resistance may undermine current efforts to control and eliminate Plasmodium vivax, the most geographically widespread yet neglected human malaria parasite. Endemic countries are expected to assess regularly the therapeutic efficacy of antimalarial drugs in use in order to adjust their malaria treatment policies, but proper funding and trained human resources are often lacking to execute relatively complex and expensive clinical studies, ideally complemented by ex vivo assays of drug resistance. Here we review the challenges for assessing in vivo P. vivax responses to commonly used antimalarials, especially chloroquine and primaquine, in the presence of confounding factors such as variable drug absorption, metabolism and interaction, and the risk of new infections following successful radical cure. We introduce a simple modeling approach to quantify the relative contribution of relapses and new infections to recurring parasitemias in clinical studies of hypnozoitocides. Finally, we examine recent methodological advances that may render ex vivo assays more practical and widely used to confirm P. vivax drug resistance phenotypes in endemic settings and review current approaches to the development of robust genetic markers for monitoring chloroquine resistance in P. vivax populations. (AU)

FAPESP's process: 20/00433-8 - Beyond pvmdr1 and pvcrt: search for relevant diversity in new Plasmodium vivax candidate genes associated with antimalarial drug resistance
Grantee:Marcelo Urbano Ferreira
Support Opportunities: Regular Research Grants